Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
307 USD | -0.36% | -2.03% | -15.02% |
May. 30 | JPMorgan Adjusts Price Target on Molina Healthcare to $420 From $435 | MT |
May. 30 | Baird Initiates Molina Healthcare With Outperform Rating, $405 Price Target | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.37 times its sales.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.02% | 18.06B | B- | ||
+13.41% | 125B | A- | ||
+11.30% | 94.92B | B- | ||
-21.60% | 43.15B | A- | ||
-7.11% | 36.81B | B- | ||
-27.43% | 2.6B | C+ | ||
-3.37% | 1.55B | B- | ||
+14.48% | 511M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MOH Stock
- Ratings Molina Healthcare, Inc.